7 Grants
2019
Combination Therapy: Targeting Pancreatic Cancer with a ROS Inducer and Gemcitabine
REINDL, KATIE
National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (ID: 5P20GM109024-04-5956), $202,991USD, 2019
2018
Combination Therapy: Targeting Pancreatic Cancer with a ROS Inducer and Gemcitabine
REINDL, KATIE
National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (ID: 5P20GM109024-03-5956), $173,042USD, 2018
2017
Combination Therapy: Targeting Pancreatic Cancer with a ROS Inducer and Gemcitabine
REINDL, KATIE
National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (ID: 5P20GM109024-02-5956), $212,806USD, 2017
2016
Combination Therapy: Targeting Pancreatic Cancer with a ROS Inducer and Gemcitabine
REINDL, KATIE
National Institutes of Health (NIH), National Institute of General Medical Sciences (NIGMS) (ID: 1P20GM109024-01A1-5956), $217,500USD, 03/01/2016 -- 02/28/2021
 
Piperlongumine as a Novel Radiosensitizer for Lung Cancer
CHRISTOFIDOU-SOLOMIDOU, MELPO and REINDL, KATIE
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 5R21CA178654-02), $167,149USD, 03/01/2015 -- 02/28/2018
2015
Piperlongumine as a Novel Radiosensitizer for Lung Cancer
CHRISTOFIDOU-SOLOMIDOU, MELPO and REINDL, KATIE
National Institutes of Health (NIH), National Cancer Institute (NCI) (ID: 1R21CA178654-01A1), $211,568USD, 03/01/2015 -- 02/28/2017
2009
Broadening the Accessibility and Portability of Biology Animations
White, AlanWood, NathanReindl, KatieSlator, Brian and Mc Clean, Phillip
National Science Foundation (NSF), Directorate for Education & Human Resources, Division of Undergraduate Education (ID: 0918955), $494,900USD, 09/01/2009 -- 08/31/2013